Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2659)	9/27/2001 9:11:21 PM
From: keokalani'nui	Respond to of 4974

Valentis files for $45 mln mixed shelf WASHINGTON, Sept 27 (Reuters) - Biopharmaceutical firm Valentis Inc. (NasdaqNM:VLTS - news) filed with U.S. regulators on Thursday to periodically offer up to $45 million worth of equity warrants, preferred and common stock. The firm plans to use proceeds from the sale for general corporate purposes, which may include research, development and product manufacturing, reducing debt, acquisitions or other business investments, it said in the Securities and Exchange Commission document. Under such a filing, a company may sell securities from time to time in one or more separate offerings in amounts, at prices and on terms to be determined at the time of sale. The Burlingame, California firm converts genomics discoveries into medicine. It shares closed down 10 cents to $3.45, having traded as high as $10.94 and as low as $2.70 over the past year.